izpis_h1_title_alt

Celično zdravljenje s tolerogenimi dendritičnimi celicami - vzročno zdravljenje avtoimunskih bolezni
Švajger, Urban (Author), Jeras, Matjaž (Author)

URLURL - Presentation file, Visit http://szd.si/user_files/vsebina/Zdravniski_Vestnik/2013/januar/47-54.pdf This link opens in a new window

Abstract
Izhodišča: Dendritične celice (DC) v človeškem organizmu so poglavitni prenašalci antigenske (Ag) informacije. Le-to posredujejo Ag-specifičnim limfocitom T v različnem smislu imunske aktivacije, ki je lahko imunostimulativna oz. imunosupresivna. Slednje je odvisno od njihovega aktivacijskega stanja, pri čemer izražajo DC izjemno funkcijsko plastičnost. Tolerogene DC, ki jih označujejo izrazite imunosupresivne značilnosti, lahko inducirajo nastanek regulacijskih limfocitov T ter povzročijo nastanek T celične anergije. V zadnjih dveh desetletjih se je nabralo dovolj eksperimentalnih dokazov na živalskih modelih, ki nakazujejo varnost in učinkovitost uporabe DC za zdravljenje imunsko posredovanih bolezni. Imunoterapija z DC tako postaja klinična stvarnost. Trenutno je v okviru NIH (National Institutes of Health) registrirana klinična študija za uporabo avtolognih DC, pridobljenih iz človeških monocitov, spremenjenih v pogojih ex vivo v smislu indukcije imunosupresivnih lastnosti, za zdravljenje avtoimunskega diabetesa tipa 1. Zaključki: Pregledni članek opisuje poglavitne lastnosti DC, primernih za uporabo v celičnem zdravljenju avtoimunskih bolezni, njihovo vlogo pri tovrstnem zdravljenju ter načine priprave te vrste celičnih pripravkov v laboratoriju. Zdravljenje avtoimunskihbolezni s tolerogenimi DC je izjemen potencial, pri čemer pa je poglavitna ovira ustrezna pridobitev celičnega proizvoda ob upoštevanju strogih načel dobre proizvodne prakse (GMP).

Language:Slovenian
Keywords:dendritične celice, avtoimunske bolezni, zdravljenje, tolerogene dendritične celice, limfociti T
Work type:Not categorized (r6)
Tipology:1.02 - Review Article
Organization:FFA - Faculty of Pharmacy
Year:2013
Number of pages:str. 47-54
Numbering:Letn. 82, št. 1
UDC:577.2+612.017
ISSN on article:1318-0347
COBISS.SI-ID:3402097 Link is opened in a new window
Views:842
Downloads:195
Metadata:XML RDF-CHPDL DC-XML DC-RDF
 
Average score:(0 votes)
Your score:Voting is allowed only to logged in users.
:
Share:AddThis
AddThis uses cookies that require your consent. Edit consent...

Record is a part of a journal

Title:Zdravniški vestnik
Publisher:Slovensko zdravniško društvo
ISSN:1318-0347
COBISS.SI-ID:32893696 This link opens in a new window

Secondary language

Language:English
Title:Tolerogenic dendritic cell therapy - causal treatment of autoimmune diseases
Abstract:
Background: Dendritic cells (DCs) are considered as primary carriers of antigenic (Ag) information in the human body. This information is later presented to Ag-specific T lymphocytes in various ways that can be either immunostimulating or immunosuppressive. The latter depends on the activation status of DCs, in which way the DCs display extreme plasticity in terms of their function. Tolerogenic DCs, which are characterized by extensive immunosuppressive properties, can induce the generation of regulatory T lymphocytes or cause T-cell anergy. In the last two decades, considerable evidence has accumulated using animal models, which points to safety and efficacy of DC application in terms of treating immune-mediated diseases. Immun therapy using DCs is nowadays becoming a clinical reality. At present, a clinical study using autologous DCs derived from human monocytes and treated ex vivo to induce their immunosuppressive potential, with the aim to treat autoimmune type 1 diabetes, is registered within NIH (National Institutes of Health). Conclusion: The review discusses the characteristics of DCs, suitable for use in cellular therapy of autoimmune diseases, their role in such therapies and the way in which such cells can be generated in the laboratory. Therapy of autoimmune diseases using tolerogenic DCs represents an outstanding potential, however the major obstacles lay in the way of proper preparation of cellular products, where all procedures should follow the strict demands of good manufacturing practice (GMP).


Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Comments

Leave comment

You have to log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back